Active vitamin D treatment in the prevention of sarcopenia in adults with prediabetes (DPVD ancillary study): a randomised controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

For the Japanese translation of the abstract see Supplementary Materials section.

Who Took Part

The study group was 28 men.

PubMed tags the participants as both men and women.

Participants were assigned (1:1) by using a central randomisation method in which a randomisation list was made for each hospital separately using a stratified permuted block procedure.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

This randomised, double-blind, placebo-controlled, multicenter trial as an ancillary study was conducted at 32 clinics and hospital sites in Japan.

This study is registered with the UMIN clinical trials registry, UMIN000005394.

What Was Measured

PubMed files the paper under topics including Hand Strength, Hypercalcemia, Prediabetic State, Sarcopenia, Vitamin D and Vitamins.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 28 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (The lancet. Healthy longevity), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.